Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease

The European Journal of Neuroscience
S CrottyY Nolan

Abstract

Administration of VP025 (Vasogen Inc.), a novel drug formulation based on phospholipid nanoparticles incorporating phosphatidylglycerol, has previously been shown to have a neuroprotective effect in the brain. We examined the effect of VP025 in a rat model of Parkinson's disease, the 6-hydroxydopamine (6-OHDA) lesion of the medial forebrain bundle. VP025 or phosphate-buffered saline (PBS) was administered to rats 14 days, 13 days and 1 day before the unilateral 6-OHDA lesion. Functional integrity of nigrostriatal dopaminergic neurons was assessed 7 and 21 days later by amphetamine-induced rotational testing and we observed that rotational counts were significantly less in rats that were pretreated with VP025 compared with PBS-pretreated 6-OHDA-lesioned rats. Neurochemical analysis at 10 and 28 days after lesion revealed that VP025 protected against a 6-OHDA-induced decrease in concentrations of striatal dopamine and its metabolites. Immunocytochemical studies of the ipsilateral substantia nigra showed that VP025 significantly inhibited 6-OHDA-induced loss of dopaminergic neurons. We also observed that increases in immunostaining for activated microglia and for activated p38 in dopaminergic neurons of 6-OHDA-lesioned rats were p...Continue Reading

References

Jul 10, 2003·Lancet Neurology·Murat Emre
Aug 30, 2003·The Journal of Biological Chemistry·Masahito HashimotoTomohiko Ogawa
Jun 3, 2004·Lancet·Ali SamiiBruce R Ransom
Jul 13, 2004·Current Opinion in Neurology·Yvette A M GrimbergenBastiaan R Bloem
Dec 14, 2004·The New England Journal of Medicine·Stanley FahnUNKNOWN Parkinson Study Group
Apr 12, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·C Warren Olanow, Joseph Jankovic
Oct 18, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·A H V Schapira
Feb 21, 2006·Lancet Neurology·K Ray ChaudhuriUNKNOWN National Institute for Clinical Excellence
Sep 20, 2006·Journal of Neurochemistry·Rebecca GriffinMarina A Lynch

❮ Previous
Next ❯

Citations

Dec 3, 2009·Antioxidants & Redox Signaling·Sergio Rosales-CorralGabriela Lopez-Armas
Oct 13, 2011·Journal of Neuroinflammation·Janelle Drouin-OuelletFrancesca Cicchetti
Jul 4, 2009·Nanomedicine·Ari NowacekHoward E Gendelman
Feb 19, 2011·Parkinson's Disease·Kemal Ugur TufekciKursad Genc
May 16, 2014·SpringerPlus·Louise M CollinsAndré Toulouse
Oct 21, 2014·PloS One·Chandramohan WakadeJohn Morgan
Aug 14, 2009·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Galina DvoriantchikovaDmitry Ivanov
Feb 10, 2017·Journal of Biomaterials Applications·Daniela Silva AdayaEmma Ortiz-Islas
Mar 2, 2017·Neurochemical Research·Pei ZhangLei Zhao
Aug 9, 2018·Nanomedicine·Weiyuan ZhangZhiyong He
Feb 18, 2010·Medicinal Research Reviews·Christian CeliaMassimo Fresta
Sep 13, 2014·Molecular Medicine Reports·Junqiang YanGanqin Du
May 14, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Abuzer Alp YetisginOzlem Kutlu
Dec 18, 2008·Expert Review of Neurotherapeutics·David B Sommer, Mark A Stacy
Sep 10, 2020·Progress in Neurobiology·Ning AnBart P F Rutten
Aug 19, 2009·Progress in Neurobiology·Caitríona M Long-SmithYvonne M Nolan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.